New cancer drug CHS-114 enters first human tests

NCT ID NCT05635643

Ongoing Disease control Sponsor: Coherus Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 7 times

Summary

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles the drug. About 87 adults with advanced solid tumors or head and neck cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CHS-114 (a monoclonal antibody targeting CCR8) and toripalimab (an immunotherapy drug)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 87 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it will take years before any potential treatment is available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center

Detroit, Michigan, 48201, United States
Emory Winship Cancer Institute

Atlanta, Georgia, 30308, United States
START Mountain

West Valley City, Utah, 84119, United States
START- San Antonio

San Antonio, Texas, 78229, United States
Stanford Cancer Center

Palo Alto, California, 94305, United States
University of Cincinnati

Cincinnati, Ohio, 45219, United States
University of Louisville

Louisville, Kentucky, 40202, United States
University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201, United States
University of Michigan

Ann Arbor, Michigan, 48104, United States
University of Washington/Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37203, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.